Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	0.02	0.1	0.16	114.09
Revenue Growth (YoY)	-	-76.84%	-39.10%	-99.86%	-
Gross Profit	-	0.02	0.1	0.16	114.09
Selling, General & Admin	56.78	65.21	71.67	79.31	74.11
Research & Development	150.15	192.3	242.91	256.39	220.18
Other Operating Expenses	2.38	15.72	13.25	-	-
Total Operating Expenses	209.32	273.22	327.83	335.69	294.28
Operating Income	-209.32	-273.2	-327.74	-335.54	-180.19
Interest Income	19.29	20.15	18.31	4.57	1.71
Interest Expense	-1.08	-0.18	-	-	-
Other Non-Operating Income (Expense)	0.22	-3.92	-17.84	-9.44	-3.57
Total Non-Operating Income (Expense)	18.43	16.05	0.47	-4.88	-1.86
Pretax Income	-190.89	-257.15	-327.27	-340.41	-182.05
Provision for Income Taxes	-	-0.44	-	-	-
Net Income	-190.89	-257.59	-327.27	-340.41	-182.05
Net Income to Common	-190.89	-257.59	-327.27	-340.41	-182.05
Shares Outstanding (Basic)	221	195	157	143	136
Shares Outstanding (Diluted)	221	195	157	143	136
Shares Change (YoY)	13.25%	24.14%	9.63%	5.39%	12.84%
EPS (Basic)	-0.87	-1.32	-2.09	-2.38	-1.34
EPS (Diluted)	-0.87	-1.32	-2.09	-2.38	-1.34
Free Cash Flow	-149.63	-200.99	-239.25	-225.71	-206.26
Free Cash Flow Per Share	-0.68	-1.03	-1.52	-1.58	-1.52
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-1241813.64%	-344986.32%	-215087.18%	-157.94%
Profit Margin	-	-1166836.36%	-344489.47%	-218214.10%	-159.57%
FCF Margin	-	-913609.09%	-251841.05%	-144685.90%	-180.79%
EBITDA	-196.96	-259.56	-313.54	-321.24	-169.74
EBITDA Margin	-	-1179818.18%	-330040.00%	-205923.72%	-148.78%
EBIT	-209.32	-273.2	-327.74	-335.54	-180.19
EBIT Margin	-	-1241813.64%	-344986.32%	-215087.18%	-157.94%
Effective Tax Rate	0.00%	0.17%	0.00%	0.00%	0.00%

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q